
Releases
Cytonics Concludes Phase 1 Trials for Osteoarthritis Drug CYT-108
Jupiter-based biopharmaceutical firm Cytonics Corporation has finalized the clinical study report for its first-in-human trial of CYT-108, a recombinant protein therapy designed to treat knee osteoarthritis. The milestone transitions the company toward upcoming Phase 1b/2a development stages and broader regulatory engagement for its lead biologic candidate.


















%20(1).webp)






